MDL | MFCD00148948 |
---|---|
Molecular Weight | 305.16 |
Molecular Formula | C6H6Cl2N2O4S2 |
SMILES | O=S(C1=CC(Cl)=C(Cl)C(S(=O)(N)=O)=C1)(N)=O |
Dichlorphenamide (Diclofenamide) is an orally active, specific, carbonic anhydrase inhibitor . Dichlorphenamide can reduce intraocular pressure by inhibiting the secretion of water from the eye. Dichlorphenamide can be used for glaucoma research [1] .
Dichlorphenamide can reduce IOP locally in male albino rabbits
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model: | Male albino rabbits (approximately 2.5 kg) |
Dosage: | 50 μL 10% aqueous solutions of dichlorphenamide sodium or 2 mg/kg, 6 mg/kg |
Administration: | Eye drop of 50 μL or Oral gavage of 2 mg/kg or 6 mg/kg, 5 hours |
Result: | Showed significant decrease in IOP at 30 min by instilling into eyes and decrease in IOP only at 1 h by orally after drug administration, and demonstrated that drug levels were significantly higher in the iris ciliary body and lower in the serum by instilling compared to oral administration. |
NCT Number | Sponsor | Condition | Start Date | Phase |
---|---|---|---|---|
NCT00494507 | University of Rochester|National Institute of Neurological Disorders and Stroke (NINDS) |
Hyperkalemic Periodic Paralysis|Hypokalemic Periodic Paralysis
|
June 2007 | Phase 3 |
NCT00004802 | National Center for Research Resources (NCRR)|Ohio State University|Office of Rare Diseases (ORD) |
Paralysis, Hyperkalemic Periodic|Hypokalemic Periodic Paralysis|Paramyotonia Congenita
|
June 1992 | Phase 3 |
Solid
Room temperature in continental US; may vary elsewhere.
Powder | -20°C | 3 years |
---|---|---|
4°C | 2 years | |
In solvent | -80°C | 6 months |
-20°C | 1 month |
DMSO : 100 mg/mL ( 327.70 mM ; Need ultrasonic)
Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
---|
1 mM | 3.2770 mL | 16.3848 mL | 32.7697 mL |
5 mM | 0.6554 mL | 3.2770 mL | 6.5539 mL |
10 mM | 0.3277 mL | 1.6385 mL | 3.2770 mL |